• Cost of care
• Patient-reported outcomes
• Efficacy outcome measures

• Normal, MDS, and leukemic stem cells
• Clonal diversity & evolution
• MDS Mouse models (GEMMS, PDX)
• Somatic mutations
• Spliceosome machinery
• Gene expression profiling
• Epigenetic deregulation
• Immune deregulation
• Microenvironment and stem cell niche

• Prognostic factors of outcome and risk assessment
• Predictive factors of response to treatment

• ARCH, CCUS, ICUS
• MDS in childhood
• Hereditary MDS including predisposition syndromes
• MDS with ring sideroblasts
• Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN)
• MDS with deletion 5q
• Treatment-related MDS
• BM inflammation

Current treatment options

• Hypomethylating agents
• Lenalidomide
• Hematopoietic growth factors
• Immunosuppressive therapy

New developments

• Preclinical studies
• Phase I studies

Clinical trials

• Phase II-III

Allogeneic hematopoietic cell transplantation

• Bridging to transplantation
• Post-transplantation treatment

Supportive care

• Iron overload
• Transfusion medicine and MDS
• Geriatric issues and MDS

Quality of life